{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:55:32Z","timestamp":1789059332153,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Rett syndrome (RTT) is a severe, rare and chronic disease that necessitates long-term treatment. In March 2023, trofinetide was approved by the US Food and Drug Administration as the first treatment for RTT. Because of the constraints of clinical trials, certain delayed and infrequent adverse events (AEs) may go unreported, especially in orphan disease. Further research is required to investigate the potential AE signals of trofinetide in real-world scenarios, identify rare and severe AEs associated with this treatment, and promote the safe use of trofinetide among RTT patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The data were extracted from the FAERS database from the first quarter of 2023 to the fourth quarter of 2024. Signal mining was conducted using frequency and Bayesian methods to identify positive signals associated with trofinetide. In order to obtain similar reports, the generic name \u201ctrofinetide\u201d and commercial name \u201cDAYBUE\u201d were utilized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,293,302 AE reports were collected, with 15,266 AE reports from 2,824 patients related to trofinetide designated as the primary suspected drug. All the reports were from the United States. Signal mining identified 25 system organ classes (SOCs), involving 155 preferred terms (PTs). Gastrointestinal disorders had the highest report count, with diarrhoea being the most prominent AE with high report numbers and signal strength. Several noteworthy AEs except for gastrointestinal disorders were identified which are not included on the drug label, such as nasopharyngitis, decreased appetite, weight decreased, gastroenteritis viral, influenza and irritability. Time-to-onset analysis shows that most AEs occurred in 0\u201330\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study unveils certain potential risks associated with trofinetide in real-world applications. Medical staffs should pay more attention to AEs of patients on the first month.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1643906","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:41:49Z","timestamp":1768372909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"17","author":[{"given":"Xihui","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Meizhou People\u2019s Hospital (Huangtang Hospital)","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuomiao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Meizhou People\u2019s Hospital (Huangtang Hospital)","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaofeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College","place":["Shantou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12887-024-04526-3","article-title":"Safety and efficacy of trofinetide in Rett syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Pediatr."},{"key":"B2","first-page":"1","article-title":"Using connectivity to explain neuropsychiatric conditions: the example of autism","volume-title":"Handbook of neuroengineering","author":"Adamek","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1750-1172-9-87","article-title":"Twenty years of surveillance in Rett syndrome: what does this tell us?","volume":"9","author":"Anderson","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/dddt.S383133","article-title":"Profile of trofinetide in the treatment of Rett syndrome: design, development and potential place in therapy","volume":"18","author":"Camillo","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e000717","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatr. Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2141\/jpsa.0180127","article-title":"Role of insulin-like growth Factor-1 in the central regulation of feeding behavior in chicks","volume":"56","author":"Fujita","year":"2019","journal-title":"J. Poult. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/wnl.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41572-024-00568-0","article-title":"Rett syndrome","volume":"10","author":"Gold","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41586-020-2369-7","article-title":"IGF1R is an entry receptor for respiratory syncytial virus","volume":"583","author":"Griffiths","year":"2020","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jama.2023.4003","article-title":"Trofinetide receives FDA approval as first drug for Rett syndrome","volume":"329","author":"Harris","year":"2023","journal-title":"Jama"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e70051","DOI":"10.1111\/jar.70051","article-title":"Middle-aged women with Rett syndrome: longitudinal profile from the British Isles Rett syndrome survey and suggestions for care","volume":"38","author":"Hryniewiecka-Jaworska","year":"2025","journal-title":"J. Appl. Res. Intellect. Disabil."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e5768","DOI":"10.1002\/pds.5768","article-title":"Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review","volume":"33","author":"Jiao","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"838206","DOI":"10.3389\/fneur.2022.838206","article-title":"Multimodal neuroimaging in Rett syndrome with MECP2 mutation","volume":"13","author":"Kong","year":"2022","journal-title":"Front. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1210\/endrev\/bnaf022","article-title":"Opposing metabolic effects of growth hormone and IGF-I: review and clinical implications","volume":"46","author":"Laron","year":"2025","journal-title":"Endocr. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1485190","DOI":"10.3389\/fphar.2024.1485190","article-title":"A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"fcae413","DOI":"10.1093\/braincomms\/fcae413","article-title":"Differential functional change in olfactory bulb and olfactory eloquent areas in parkinson's disease","volume":"6","author":"Luo","year":"2024","journal-title":"Brain Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678707.2023.2217328","article-title":"Recommendations for the management of diarrhea with trofinetide use in Rett syndrome","volume":"11","author":"Marsh","year":"2023","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12883-023-03181-y","article-title":"Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study","volume":"23","author":"May","year":"2023","journal-title":"BMC Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e230054","DOI":"10.57264\/cer-2023-0054","article-title":"Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data","volume":"13","author":"May","year":"2024","journal-title":"J. Comp. Eff. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/17474124.2024.2368014","article-title":"Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome","volume":"18","author":"Motil","year":"2024","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.brainresbull.2018.09.017","article-title":"Antidepressant-like effects of insulin and IGF-1 are mediated by IGF-1 receptors in the brain","volume":"143","author":"Mueller","year":"2018","journal-title":"Brain Res. Bull."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e01250","DOI":"10.1002\/brb3.1250","article-title":"Epilepsy and genetic in Rett syndrome: a review","volume":"9","author":"Operto","year":"2019","journal-title":"Brain Behav."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1172805","DOI":"10.3389\/fnins.2023.1172805","article-title":"Advanced genetic therapies for the treatment of Rett syndrome: state of the art and future perspectives","volume":"17","author":"Palmieri","year":"2023","journal-title":"Front. Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.tips.2023.06.008","article-title":"Trofinetide: a pioneering treatment for Rett syndrome","volume":"44","author":"Parent","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/biom11010075","article-title":"Role of DNA Methyl-CpG-Binding protein MeCP2 in Rett syndrome pathobiology and mechanism of disease","volume":"11","author":"Pejhan","year":"2021","journal-title":"Biomolecules"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.medj.2024.05.018","article-title":"Trofinetide for the treatment of Rett syndrome: results from the open-label extension LILAC study","volume":"5","author":"Percy","year":"","journal-title":"Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.medj.2024.06.007","article-title":"Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results of the 32-month, open-label LILAC-2 study","volume":"5","author":"Percy","year":"","journal-title":"Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.resp.2013.06.022","article-title":"Breathing challenges in Rett syndrome: lessons learned from humans and animal models","volume":"189","author":"Ramirez","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/088307380001500114","article-title":"Syndrome of microcephaly, mental retardation, and tracheoesophageal fistula associated with features of Rett syndrome","volume":"15","author":"Shetty","year":"2000","journal-title":"J. Child. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","article-title":"Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice","volume":"106","author":"Tropea","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/genes14081607","article-title":"Multidisciplinary management of Rett syndrome: twenty years' experience","volume":"14","author":"Vilvarajan","year":"2023","journal-title":"Genes (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1486597","DOI":"10.3389\/fphar.2024.1486597","article-title":"Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system","volume":"15","author":"Zhong","year":"2024","journal-title":"FAERS"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1643906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:39:34Z","timestamp":1771911574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1643906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":36,"alternative-id":["10.3389\/fphar.2026.1643906"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1643906","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1643906"}}